Analyst Reco. Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-21 EDT			5-day change	1st Jan Change
4.08 ^USD	+2.51%		-2.39%	-45.31%

06-05	Transcript : Acelyrin, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:00 PM
06-05	ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	05-22	MT
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	03-21	MT
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target	12-13	MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target	12-08	MT
Morgan Stanley Adjusts Price Target on ACELYRIN to $13 From $19, Maintains Equal-Weight Rating	11-28	MT
Jefferies Adjusts ACELYRIN Price Target to $12 From $15, Maintains Buy Rating	11-28	MT
Morgan Stanley Downgrades ACELYRIN to Equalweight From Overweight, Cuts Price Target to $19 From $39	23-09-13	MT
Morgan Stanley Adjusts Price Target on Acelyrin to $39 From $29, Maintains Overweight Rating	23-09-05	MT
HC Wainwright Starts Acelyrin at Buy, $44 Price Target	23-09-05	MT
Morgan Stanley Initiates Coverage on Acelyrin With Overweight Rating, $29 Price Target	23-05-30	MT
Jefferies Starts Acelyrin at Buy With $31 Price Target	23-05-30	MT
Piper Sandler Initiates Acelyrin at Overweight With $68 Price Target	23-05-30	MT
TD Cowen Starts Acelyrin at Outperform	23-05-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer